These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17159603)

  • 1. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
    Qiu Q; Domarkas J; Banerjee R; Katsoulas A; McNamee JP; Jean-Claude BJ
    Anticancer Drugs; 2007 Feb; 18(2):171-7. PubMed ID: 17159603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
    Matheson SL; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
    Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
    Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ
    Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
    Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
    J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.
    Fang Y; Qiu Q; Domarkas J; Larroque-Lombard AL; Rao S; Rachid Z; Gibbs BF; Gao X; Jean-Claude BJ
    Prostate; 2012 Sep; 72(12):1273-85. PubMed ID: 22290742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
    Matheson SL; McNamee JP; Wang T; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
    Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line.
    Qiu Q; Dudouit F; Banerjee R; McNamee JP; Jean-Claude BJ
    Prostate; 2004 Apr; 59(1):13-21. PubMed ID: 14991862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
    Qiu Q; Dudouit F; Matheson SL; Brahimi F; Banerjee R; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):1-10. PubMed ID: 12497200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
    Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
    J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
    Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
    Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.
    Banerjee R; Rachid Z; McNamee J; Jean-Claude BJ
    J Med Chem; 2003 Dec; 46(25):5546-51. PubMed ID: 14640561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced isoflavone metabolites formed by the human gut microflora suppress growth but do not affect DNA integrity of human prostate cancer cells.
    Raschke M; Wähälä K; Pool-Zobel BL
    Br J Nutr; 2006 Sep; 96(3):426-34. PubMed ID: 16925846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
    Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
    J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.
    Larroque-Lombard AL; Todorova M; Golabi N; Williams C; Jean-Claude BJ
    J Med Chem; 2010 Mar; 53(5):2104-13. PubMed ID: 20151639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.
    Matheson SL; McNamee J; Jean-Claude BJ
    J Pharmacol Exp Ther; 2001 Mar; 296(3):832-40. PubMed ID: 11181914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
    Matheson SL; Brahimi F; Jean-Claude BJ
    Biochem Pharmacol; 2004 Mar; 67(6):1131-8. PubMed ID: 15006549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
    Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
    J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
    Rachid Z; Macphee M; Williams C; Todorova M; Jean-Claude BJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5505-9. PubMed ID: 19665377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.